Research programme: hepatitis C virus NS5A inhibitors - Presidio Pharmaceuticals

Drug Profile

Research programme: hepatitis C virus NS5A inhibitors - Presidio Pharmaceuticals

Alternative Names: HCV NS5A inhibitors - Presidio Pharmaceuticals; PPI-1301; PPI-437; PPI-833; XTL-DOS

Latest Information Update: 24 Feb 2012

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator XTL Biopharmaceuticals
  • Developer Presidio Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hepatitis C

Most Recent Events

  • 24 Feb 2012 Presidio Pharmaceuticals' hepatitis C virus NS5A inhibitors programme is available for licensing. http://www.presidiopharma.com/
  • 26 May 2010 Presidio selects a second clinical candidate, PPI 1301, for evaluation in IND-enabling studies
  • 22 Jul 2009 Presidio raises a further $US27 million to advance its NS5A inhibitors into clinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top